GE HealthCare sets October 28 results date: analysts target GE HealthCare stock at USD 78.35

Published on 10/20/2026 at 21:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 5.29 billion, up 5.80 percent year over year. GE HealthCare stock costs EUR 62.09 on October 20, 2026.

Reporting date October 28, 2026

GE HealthCare will publish third-quarter 2026 results on October 28, 2026.
Second-quarter revenue reached USD 5.29 billion, up 5.80 percent year over year.
GE HealthCare stock costs EUR 62.09 at Lang & Schwarz on October 20, 2026 at 9:31 p.m. CEST.
Analysts tracked by MarketBeat set an average 12-month target of USD 78.35 across 22 brokerages.

Isometrische Illustration zeigt Wertschöpfungskette von Forschung über Produktion bis Patientenversorgung — GE HealthCare US36266G1076 als isometrisches 3D Diagramm der medizintechnischen Wertschöpfungskette von Forschung bis Patient, Illustration mit AI erstellt.

GE HealthCare will publish its third-quarter 2026 results on October 28, 2026, while analysts tracked by MarketBeat set an average 12-month target of USD 78.35 across 22 brokerages. The company’s second-quarter revenue reached USD 5.29 billion, up 5.80 percent year over year, and adjusted earnings per share came to USD 1.13, according to MarketBeat. GE HealthCare stock was at EUR 62.09 at Lang & Schwarz on October 20, 2026 at 9:31 p.m. CEST.

Analysts keep a USD 78.35 target

MarketBeat reported on October 15, 2026 that 22 brokerages had a consensus rating of Moderate Buy and an average 12-month price target of USD 78.35. The breakdown included 11 Buy ratings, 10 Hold ratings and one Strong Buy rating. The average target is a separate US-dollar valuation reference and is not combined with the euro quotation.

BTIG Research cut its target from USD 79.00 to USD 75.00 while retaining a Buy rating in a report dated October 12, 2026, as reported by MarketBeat. Citigroup had cut its target from USD 75.00 to USD 71.00 on October 5, 2026, while Barclays upgraded its rating to Strong Buy on October 7, 2026, according to MarketBeat.

Revenue and earnings set the baseline

The second-quarter revenue figure of USD 5.29 billion exceeded the USD 5.26 billion consensus estimate, while adjusted earnings per share of USD 1.13 exceeded the USD 1.04 estimate. That combination gives investors two concrete benchmarks before the October report. GE HealthCare’s primary listing is Nasdaq under ticker GEHC, and the company operates across imaging, ultrasound, patient care solutions and pharmaceutical diagnostics.

What comes next for GE HealthCare?

The company’s investor-relations release dated October 7, 2026 said the third-quarter report would be issued before the Nasdaq open on October 28, 2026, with a conference call scheduled for 8:30 a.m. ET. The release described GE HealthCare as a USD 20.6 billion business with approximately 54,000 colleagues, according to GE HealthCare.

Stock price and valuation

GE HealthCare was last quoted at USD 69.88 on Nasdaq on October 20, 2026 at 3:33 p.m. ET, with a market capitalization of USD 31.6 billion, a price-to-earnings ratio of 20.22 and a 52-week range of USD 58.75 to USD 89.77. The euro quotation from Lang & Schwarz was EUR 62.09 at 9:31 p.m. CEST on October 20, 2026.

Market position before results

For investors, the key comparison is between the USD 78.35 consensus target and the company’s USD 69.88 Nasdaq quotation, while the next earnings date provides the immediate scheduled event. GE HealthCare’s second-quarter revenue growth of 5.80 percent and its USD 1.13 adjusted earnings per share now form the operating baseline for the October release.

Euro quote remains the daily marker

The Lang & Schwarz quotation stood at EUR 62.09 on October 20, 2026 at 9:31 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of GE HealthCare stock.